Participants

Committee members participating in all or part of the meeting: Stephen J. Wolf, MD, FACEP, Chair; Richard Byyny, MD, MSc, FACEP, Methodologist; Stephen V. Cantrill, MD, FACEP, Liaison with Quality & Patient Safety Committee, and to the E-QUAL Steering Committee; Christopher R. Carpenter, MD, MSc, FACEP; Deborah B. Diercks, MD, MSc, FACEP; Seth R. Gemme, MD, FACEP; Charles J. Gerardo, MD, MHS, FACEP; Steven A. Godwin, MD, FACEP; Sigrid A. Hahn, MD, MPH; Benjamin W. Hatten, MD, MPH, FACEP; Sean M. Hickey, MD, EMRA Representative; Jon Mark Hirshon, MD, PhD, MPH, FACEP, Board Liaison; Amy Kaji, MD, MPH, PhD, Methodologist; Bruce M. Lo, MD, MBA, RDMS, FACEP; Sharon E. Mace, MD, FACEP, FAAP; Susan B. Promes, MD, MBA, FACEP; Kaushal H. Shah, MD, FACEP; Richard D. Shih, MD, FACEP; Scott M. Silvers, MD, FACEP; Michael D. Smith, MD, MBA, FACEP; Molly E.W. Thiessen, MD; Christian A. Tomaszewski, MD, MS, MBA, FACEP; Jonathan H. Valente, MD, FACEP; Yanling Yu, PhD, Patient Representative.

Also present for all or part of the meeting: Mandie Mims, MLS, Staff Liaison; Travis Schulz, MLS, AHIP, Staff Liaison.

Agenda

1. Stroke Clinical Policy – Critical Question 4
2. Strategic Review – Process Assessment

Major Points Discussed

1. Stroke Clinical Policy – Critical Question 4

   Dr. Lo led the discussion on critical question 4 of the stroke clinical policy. Two question options were presented to the committee, and the committee voted on which elements they felt were the most applicable. After a lengthy discussion, it was decided that the stroke subcommittee will make the requested edits to the question and send a final draft to the committee for review.

2. Strategic Review – Process Assessment

   Dr. Hatten and Dr. Godwin led a brief discussion on the state of the process assessment workgroup. A longer discussion has been scheduled for the October conference call of the Clinical Policies Committee.